Targeting TGF-beta: triumphs and challenges

被引：2
作者：
Acharya, Baku [1 ]
Miah, Sayem [2 ]
Frett, Brendan [1 ]
机构：
[1] Univ Arkansas Med Sci, Coll Pharm, Dept Pharmaceut Sci, Little Rock, AR 72205 USA
[2] Univ Arkansas Med Sci, Coll Med, Dept Biochem & Mol Biol, Little Rock, AR 72205 USA
来源：
FUTURE MEDICINAL CHEMISTRY | 2022年 / 14卷 / 07期
关键词：
clinical translation; immunoncology; oncology; pleiotropy; temporal; TGF-beta; tumor microenvironment;
D O I：
10.4155/fmc-2021-0344
中图分类号：
R914 [药物化学];
学科分类号：
100701 ;
摘要：
The presence of elevated TGF-beta levels in tumor cells, along with its tumor-promoting roles, makes the cytokine an attractive, yet enigmatic, target.
引用
收藏
页码：455 / 458
页数：4
相关论文
共 20 条
  • [1] Attenuation of TGF-β signaling supports tumor progression of a mesenchymal-like mammary tumor cell line in a syngeneic murine model
    Biswas, Tanuka
    Gu, Xiang
    Yang, Junhua
    Ellies, Lesley G.
    Sun, Lu-Zhe
    [J]. CANCER LETTERS, 2014, 346 (01) : 129 - 138
  • [2] Targeting TGF-β Signaling in Cancer
    Colak, Selcuk
    ten Dijke, Peter
    [J]. TRENDS IN CANCER, 2017, 3 (01): : 56 - 71
  • [3] α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by -TGF antibody to promote durable rejection and immunity in squamous cell carcinomas
    Dodagatta-Marri, E.
    Meyer, D. S.
    Reeves, M. Q.
    Paniagua, R.
    To, M. D.
    Binnewies, M.
    Broz, M. L.
    Mori, H.
    Wu, D.
    Adoumie, M.
    Del Rosario, R.
    Li, O.
    Buchmann, T.
    Liang, B.
    Malato, J.
    Arce Vargus, F.
    Sheppard, D.
    Hann, B. C.
    Mirza, A.
    Quezada, S. A.
    Rosenblum, M. D.
    Krummel, M. F.
    Balmain, A.
    Akhurst, R. J.
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [4] TGF-beta/atRA-induced Tregs express a selected set of microRNAs involved in the repression of transcripts related to Th17 differentiation
    dos Santos Schiavinato, Josiane Lilian
    Haddad, Rodrigo
    Saldanha-Araujo, Felipe
    Baiochi, Joao
    Araujo, Amelia Goes
    Scheucher, Priscila Santos
    Covas, Dimas Tadeu
    Zago, Marco Antonio
    Panepucci, Rodrigo Alexandre
    [J]. SCIENTIFIC REPORTS, 2017, 7
  • [5] Hau P, 2005, J CLIN ONCOL, V23, p123S
  • [6] Recent progress in TGF-β inhibitors for cancer therapy
    Huang, Cheng-Yi
    Chung, Chih-Ling
    Hu, Tsung-Hui
    Chen, Jih-Jung
    Liu, Pei-Feng
    Chen, Chun-Lin
    [J]. BIOMEDICINE & PHARMACOTHERAPY, 2021, 134
  • [7] A Perspective on the Development of TGF-β Inhibitors for Cancer Treatment
    Huynh, Linh Khanh
    Hipolito, Christopher John
    ten Dijke, Peter
    [J]. BIOMOLECULES, 2019, 9 (11)
  • [8] Population pharmacokinetics of vactosertib, a new TGF-β receptor type Ι inhibitor, in patients with advanced solid tumors
    Jung, Su Young
    Yug, Ji Seob
    Clarke, Jeffery M.
    Bauer, Todd M.
    Keedy, Vicki L.
    Hwang, Sunjin
    Kim, Seong-Jin
    Chung, Eun Kyoung
    Lee, Jangik I.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2020, 85 (01) : 173 - 183
  • [9] Pharmacokinetic characteristics of vactosertib, a new activin receptor-like kinase 5 inhibitor, in patients with advanced solid tumors in a first-in-human phase 1 study
    Jung, Su Young
    Hwang, Sunjin
    Clarke, Jeffery M.
    Bauer, Todd M.
    Keedy, Vicki L.
    Lee, Hukeun
    Park, Neunggyu
    Kim, Seong-Jin
    Lee, Jangik, I
    [J]. INVESTIGATIONAL NEW DRUGS, 2020, 38 (03) : 812 - 820
  • [10] Novel therapies emerging in oncology to target the TGF-β pathway
    Kim, Byung-Gyu
    Malek, Ehsan
    Choi, Sung Hee
    Ignatz-Hoover, James J.
    Driscoll, James J.
    [J]. JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
12